These results provide us with new perspectives regarding future therapeutics, especially focused on preventing the MAM disruption for SOD1‐ and Sig1R‐linked ALS patients, and perhaps, sporadic ALS patients. This evidence concerns the gene SIGMAR1 and amyotrophic lateral sclerosis.